货号：R-8024- 瑞格非尼;瑞戈菲尼

供应商：上海经科化学科技有限公司 

： 

:(上海经科）

号：shjkchem 

活动：消费积分可换充值卡！

规格：25mg

价格：1080元

?

本试剂（瑞格非尼;瑞戈菲尼）

仅供科研实验使用，不得用于其他用途！

介绍：

货号:R-8024

英文名称:Regorafenib, Free Base

中文名称:瑞格非尼;瑞戈菲尼

CAS号:755037-03-7

分子量:482.82

分子式:C21H15ClF4N4O3

附:

参考文献:

Regorafenib demonstrated tolerability and antitumour activity in patients with metastatic colorectal cancer (CRC) in a phase 1 clinical trail. Strumberg D., et al. "Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study." Br. J. Cancer 106: 1722-1727 (2012). In combination chemotherapy, regorafenib showed acceptable tolerability with SN-38 and irinotecan but showed no significant effect on oxaliplatin or 5-fluorouracil pharmacokinetics. Schultheis B., et al. "Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study." Ann. Oncol. 24: 1560-1567 (2013). Regorafenib showed significant activity in patients with advanced and metastatic GI stromal tumor (GIST) after failure of both imatinib and sunitinib in a phase 2 clinical trial. George S., et al. "Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial." J. Clin. Oncol. 30: 2401-2407 (2012). In a phase 2 clinical trial, regorafenib demonstrated acceptable tolerability and antitumour activity in patients with intermediate or advanced hepatocellular carcinoma (HCC) after failure of first-line sorafenib. Bruix J., et al. "Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study." Eur. J. Cancer 49: 3412-3419 (2013). In a phase 3 study, regorafenib demonstrated prolonged survival of patients with metastatic colorectal cancer after standard therapies failed. Grothey A., et al. "Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial." Lancet 381: 303-312 (2013). Regorafenib demonstrated antitumour activity as a first-line treatment for metastatic or unresectable renal-cell carcinoma in a phase 2 clinical trial. However, the drug's safety profile required close monitoring. Eisen T., et al. "Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial." Lancet Oncol. 13: 1055-1062 (2012). Oral regorafenib significantly improved progression-free survival when compared with placebo in patients with metastatic gastrointestinal stromal tumours (GIST) after failure of standard treatments in a phase 3 clinical trial. Demetri G.D., et al. "Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial." Lancet 381: 295-302 (2013).

更多产品详情请咨询我司客服！